Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 17;65(3):e02168-20.
doi: 10.1128/AAC.02168-20. Print 2021 Feb 17.

Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate

Ahizechukwu C Eke  1   2 , Kensuke Shoji  3 , Brookie M Best  4   5 , Jeremiah D Momper  4 , Alice M Stek  6 , Tim R Cressey  7   8 , Mark Mirochnick  9 , Edmund V Capparelli  4   5
Affiliations

Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate

Ahizechukwu C Eke et al. Antimicrob Agents Chemother. .

Abstract

Pharmacokinetics of drugs can be affected by physiologic changes during pregnancy. Our aim was to assess the influence of covariates on tenofovir (TFV) pharmacokinetics in pregnant and postpartum women receiving tenofovir disoproxil fumarate (TDF). Population pharmacokinetic parameter estimates and the influence of covariates were assessed using nonlinear mixed-effects modeling (NONMEM 7.4). Forty-six women had intensive pharmacokinetic evaluations during the second and third trimesters of pregnancy, with another evaluation postpartum. A two-compartment pharmacokinetic model with allometric scaling for body weight and first-order absorption best described the tenofovir plasma concentration data. Apparent oral clearance (CL/F) and volume of distribution at steady state (Vss/F) were increased during pregnancy. Weight, serum creatinine (SCr), pregnancy, albumin, and age were associated with TFV CL/F during univariate assessment, but in the multivariate analysis, changes in CL/F and Vss/F were only associated with increased body weight and enhanced renal function. Due to greater weight and lower SCr during pregnancy, CL/F was 28% higher during pregnancy than postpartum. In the final model, CL/F (liters per hour) was described as 2.07 × (SCr/0.6)0.65 × weight0.75, with a low between-subject variability (BSV) of 24%. The probability of target attainment (proportion exceeding area under the concentration-time curve of >1.99 μg·h/ml, the 10th percentile of average TFV exposure for nonpregnant historical controls) was 68%, 80%, 87%, and 93% above the target with 300 mg, 350 mg, 400 mg, and 450 mg of TDF, respectively, during pregnancy and 88%, 92%, 96%, and 98% above the target with same doses in postpartum women. Dose adjustment of TDF during pregnancy is not generally warranted, but any modification should be based on weight and renal function. (This study has been registered at ClinicalTrials.gov under identifier NCT00042289.).

Keywords: AIDS; HIV; TDF; population pharmacokinetics; postpartum; pregnancy; tenofovir; tenofovir disoproxil fumarate.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Model structure of tenofovir population pharmacokinetics. CL/F, V1/F, V2/F, Ka, and Q represent apparent clearance, volume of central compartment, volume of peripheral compartment, absorption rate constant, and intercompartmental clearance, respectively.
FIG 2
FIG 2
Spaghetti plots of tenofovir concentrations versus time (3rd trimester).
FIG 3
FIG 3
Spaghetti plots of tenofovir concentrations versus time (postpartum).
FIG 4
FIG 4
Apparent TFV clearance versus serum creatinine clearance (marker of renal function). Solid lines represent lines of identity for pregnant women, while interrupted lines represent lines of identity for nonpregnant (postpartum) women. Serum creatinine was measured in mg/dl.
FIG 5
FIG 5
Boxplot of empirical Bayesian estimates of apparent TFV clearance in pregnant and nonpregnant (postpartum) women. Horizontal line, median; box, quartiles; whisker, range of the data (boxplots).
FIG 6
FIG 6
Goodness-of-fit diagnostic plots of observed TFV concentrations versus predicted values in the population. Solid lines represent lines of identity for pregnant women, while interrupted lines represent lines of identity for nonpregnant women. A symmetrical distribution around the line of identity is observed indicating the goodness of fit of the model.
FIG 7
FIG 7
Goodness-of-fit diagnostic plots of observed TFV concentrations versus individual predicted TFV concentrations. Solid lines represent lines of identity for pregnant women, while interrupted lines represent lines of identity for nonpregnant women. A symmetrical distribution around the line of identity is observed indicating the goodness of fit of the model.
FIG 8
FIG 8
Goodness-of-fit diagnostic plots of conditional weighted residual versus time after dose for the final model. Solid lines represent lines of identity for pregnant women, while interrupted lines represent lines of identity for nonpregnant women. A symmetrical distribution around the line of identity is observed indicating the goodness of fit of the model.
FIG 9
FIG 9
Visual predictive plot (VPC) for pregnancy, 5th, 50th, and 95th percentile.
FIG 10
FIG 10
Visual predictive plot (VPC) for postpartum, 5th, 50th, and 95th percentile.
FIG 11
FIG 11
Median concentration versus time profiles for simulated pregnant and nonpregnant women derived using the final population pharmacokinetic model. Solid lines represent lines of identity for pregnant women (PREG), while interrupted lines represent lines of identity for nonpregnant women.
FIG 12
FIG 12
Simulations of tenovovir proportion exceeding AUC of >1.99 μg·h/ml in pregnant (PREG) and postpartum (PP) women.
See this image and copyright information in PMC

References

    1. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. 2020. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection, and interventions to reduce perinatal HIV transmission in the United States–August 26. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Pe.... Accessed 18 September 2020.
    1. Gilead. 2004. TRUVADA (emtricitabine and tenofovir disoproxil fumarate) tablets for oral use—drug label. https://www.gilead.com/%7E/media/files/pdfs/medicines/hiv/truvada/truvad.... Accessed 16 September 2020.
    1. Durand-Gasselin L, Van Rompay KK, Vela JE, Henne IN, Lee WA, Rhodes GR, Ray AS. 2009. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys. Mol Pharm 6:1145–1151. doi:10.1021/mp900036s. - DOI - PMC - PubMed
    1. Delahunty T, Bushman L, Robbins B, Fletcher CB. 2009. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J Chromatogr B Analyt Technol Biomed Life Sci 877:1907–1914. doi:10.1016/j.jchromb.2009.05.029. - DOI - PMC - PubMed
    1. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M, International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) P1026s Team. 2015. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med 16:502–511. doi:10.1111/hiv.12252. - DOI - PMC - PubMed

Publication types

Associated data